ArticleThe Journal of antimicrobial chemotherapy2020
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Trial
- Comparable Efficacy of Lopinavir/Ritonavir and Remdesivir in Reducing Viral Load and Shedding Duration in Patients with COVID-19.Microorganisms · 2024Article
- Coupling the Within-Host Process and Between-Host Transmission of COVID-19 Suggests Vaccination and School Closures are Critical.Bulletin of mathematical biology · 2022Article
- Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.Current pharmaceutical design · 2022Article
- Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).Frontiers in pharmacology · 2022Article
- The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.Molecular neurobiology · 2021Review
- Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.Clinical pharmacology and therapeutics · 2021Review
- Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6".Clinical pharmacokinetics · 2021Article
- Reply to the letter to the Editor "Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts".European journal of clinical pharmacology · 2021Article
- Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review.Journal of clinical pharmacology · 2021Review
- Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts.European journal of clinical pharmacology · 2021Article
- Potential Effects of COVID-19 on Cytochrome P450-Mediated Drug Metabolism and Disposition in Infected Patients.European journal of drug metabolism and pharmacokinetics · 2021Review
- Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.Journal of medical virology · 2021Article
- Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID-19. An alleged past-resolved problem.International journal of cardiology · 2021Article
- Recent progress of antiviral therapy for coronavirus disease 2019.European journal of pharmacology · 2021Review
- High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19.Frontiers in pharmacology · 2021Article
- Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.Cellular signalling · 2020Review
- COVID-19 research: an opinion piece.HIV medicine · 2020Article
- Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.Antimicrobial agents and chemotherapy · 2020Article
- Does lopinavir really inhibit SARS-CoV-2?Pharmacological research · 2020Article
Corrections and comments
- Comment on
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.